HJNO Jul/Aug 2025

MAHA REPORT 50  JUL / AUG 2025 I  HEALTHCARE JOURNAL OF NEW ORLEANS   446 HHS Releases Comprehensive Review of Medical Interventions for Children and Adolescents with Gender Dysphoria | HHS.gov. 447 https://www.ama-assn.org/press-center/ama-press-releases/ama-states-stop-interfering-health-care-transgender-children. 448 https://publications.aap.org/aapnews/news/25340/AAP-reaffirms-gender-affirming-care-policy. 449 U.S. Department of Health and Human Services. (2025). Treatment for pediatric gender dysphoria: Review of evidence and best practices. Office of Population Affairs. https://opa.hhs.gov/. 450 Aversa, Z., Atkinson, E. J., Schafer, M. J., Theiler, R. N., Rocca, W. A., Blaser, M. J., & LeBrasseur, N. K. (2021, January). Association of infant antibiotic exposure with childhood health outcomes. In Mayo Clinic Proceedings (Vol. 96, No. 1, pp. 66-77). Elsevier. 451 Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., Finkelstein, J. A., Gerber, J. S., Hyun, D. Y., Linder, J. A., Lynfield, R., Margolis, D. J., May, L. S., Merenstein, D., Metlay, J. P., Newland, J. G., Piccirillo, J. F., Roberts, R. M., Sanchez, G. V., ... Hicks, L. A. (2016). Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. JAMA, 315(17), 1864-1873. https://doi.org/10.1001/jama.2016.4151. 452 Mitre, E., Susi, A., Kropp, L. E., Schwartz, D. J., Gorman, G. H., & Nylund, C. M. (2018). Association between use of acid-suppressive medications and antibiotics during infancy and allergic diseases in early childhood. JAMA pediatrics, 172(6), e180315-e180315. 453 Bourgeois FT, Murthy S, Pinto C, Olson KL, Ioannidis JP, Mandl KD. Pediatric versus adult drug trials for conditions with high pediatric disease burden. Pediatrics. 2012;130(2):285-292. doi:10.1542/peds.2012-0139. 454 https://www.cdc.gov/vaccines/schedules/images/schedule1983s.jpg ; No new vaccines were added to the schedule between 1983-1989. 455 Centers for Disease Control and Prevention. (2025, January 16). Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger—United States, 2025. MMWR. Morbidity and Mortality Weekly Report, 74(2), 26–29. https://www.cdc.gov/mmwr/volumes/74/ wr/pdfs/mm7402a2-H.pdf. 456 Ministère de la Santé et de la Prévention. (2025, April 28). Calendrier des vaccinations 2025. https://sante.gouv.fr/prevention-en- sante/preserver-sa-sante/vaccination/ calendrier-vaccinal. 457 UK Health Security Agency. (2025, January 22). Routine childhood immunisations from 1 January 2025. https://assets.publishing.service.gov.uk/ media/678fbe6ec88969ba1bc2ada9/UKHSA_13197_Routine_Childhood_imms_schedule_04.pdf. 458 Danish Health Authority. (2019, August 20). The Danish childhood vaccination programme. Statens Serum Institut. https://en.ssi.dk/vaccination/the-danish-childhood- vaccination-programme. 459 IOM (Institute of Medicine). 2013. The childhood immunization schedule and safety: Stakeholder concerns, scientific evidence, and future studies. Washington, DC: The National Academies Press. (“Experts who addressed the committee pointed not to a body of evidence that had been overlooked but rather to the fact that existing research has not been designed to test the entire immunization schedule” and “studies designed to examine the long-term effects of the cumulative number of vaccines or other aspects of the immunization schedule have not been conducted.”). 460 National Conference of State Legislatures. (2025, May 7 March 10 ). State non-medical exemptions from school immunization requirements. https://www.ncsl.org/ health/state-non-medical-exemptions-from-school-immunization-requirements. 461 Farina S, Maio A, Gualano MR, Ricciardi W, Villani L. Childhood Mandatory Vaccinations: Current Situation in European Countries and Changes Occurred from 2014 to 2024. Vaccines (Basel). 2024 Nov 20;12(11):1296. doi: 10.3390/vaccines12111296. 462 Benn, C. S., Fisker, A. B., Rieckmann, A., Sørup, S., & Aaby, P. (2020). Vaccinology: time to change the paradigm?. The lancet infectious diseases, 20(10), e274-e283. 463 Benn, C. S., Amenyogbe, N., Björkman, A., Domínguez-Andrés, J., Fish, E. N., Flanagan, K. L., ... & Aaby, P. (2023). Implications of non-specific effects for testing, approving, and regulating vaccines. Drug Safety, 46(5), 439-448. 464 U.S. Department of Health and Human Services, Food and Drug Administration. (2006). Guidance for industry: Adverse reactions section of labeling for human prescription drug and biological products—Content and format [PDF]. https://www.fda.gov/media/72139/download. 465 Maglione, M. A., Gidengil, C., Das, L., Raaen, L., Smith, A., Chari, R., ... & Goetz, M. B. (2014). Safety of Vaccines Used for Routine Immunization in the United States. Evidence report/technology assessment, (215), 1-740. 466 Clayton, E. W., Rusch, E., Ford, A., & Stratton, K. (Eds.). (2012). Adverse effects of vaccines: evidence and causality. Institute of Medicine. 467 Gee, J., Shimabukuro, T. T., Su, J. R., Shay, D., Ryan, M., Basavaraju, S. V., ... & Anderson, S. (2024). Overview of US COVID-19 vaccine safety surveillance systems. Vaccine, 42, 125748. 468 Lazarus R. Electronic Support for Public Health - Vaccine Adverse Event Reporting System (ESP:VAERS) - Final Report. (Prepared by Harvard Pilgrim Health Care, Inc. under Grant No. R18 HS017045). Rockville, MD: Agency for Healthcare Research and Quality, 2010. See: https://digital.ahrq.gov/ahrq-funded-projects/electronic-support- public-health-vaccine-adverse-event-reporting-system#nav-publications. 469 Hibbs, B. F., Moro, P. L., Lewis, P., Miller, E. R., & Shimabukuro, T. T. (2015). Vaccination errors reported to the vaccine adverse event reporting system,(VAERS) United States, 2000–2013. Vaccine, 33(28), 3171-3178. 470 McNeil, M. M., Gee, J., Weintraub, E. S., Belongia, E. A., Lee, G. M., Glanz, J. M., ... & DeStefano, F. (2014). The Vaccine Safety Datalink: successes and challenges monitoring vaccine safety. Vaccine, 32(42), 5390-5398. 471 Fahey, K. R. (2015). The pioneering role of the Vaccine Safety Datalink Project (VSD) to advance collaborative research and distributed data networks. eGEMs, 3(1), 1195. 472 Glanz, J. M., Newcomer, S. R., Jackson, M. L., Omer, S. B., Bednarczyk, R. A., Shoup, J. A., ... & Sukumaran, L. (2016). White Paper on studying the safety of the childhood immunization schedule in the Vaccine Safety Datalink. Vaccine, 34, A1-A29. 473 U.S. Department of Health and Human Services, Health Resources and Services Administration. (n.d.). About vaccine compensation. https://www.hrsa.gov/vaccine- compensation/about. 474 42 U.S.C.300aa-27. 475 42 U.S.C.300aa-10. 476 https://www.congress.gov/118/meeting/house/117456/witnesses/HHRG-118-JU05-Wstate-SiriEsqA-20240626.pdf. 477 Elisha, E., Guetzkow, J., Shir-Raz, Y., & Ronel, N. (2024, March). Suppressing Scientific Discourse on Vaccines? Self-perceptions of researchers and practitioners. In Hec Forum (Vol. 36, No. 1, pp. 71-89). Dordrecht: Springer Netherlands. 478 American Medical Association. (2022, June 13). AMA adopts new policy aimed at addressing public health disinformation. https://www.ama - assn.org/press-center/ ama-press-releases/ama-adopts-new-policy-aimed-addressing-public-health-disinformation. 479 Ehrhardt, S., Appel, L. J., & Meinert, C. L. (2015). Trends in National Institutes of Health funding for clinical trials registered in ClinicalTrials. gov. Jama, 314(23), 2566- 2567. 480 Patsopoulos, N. A., Ioannidis, J. P., & Analatos, A. A. (2006). Origin and funding of the most frequently cited papers in medicine: database analysis. BMj, 332(7549), 1061-1064. 481 Garfield, E. (1996). Fortnightly review: how can impact factors be improved?. Bmj, 313(7054), 411-413. 482 Goldacre, B., Lane, S., Mahtani, K. R., Heneghan, C., Onakpoya, I., Bushfield, I., & Smeeth, L. (2017). Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study. Bmj, 358. 483 Kusumoto, F. M., Bittl, J. A., Creager, M. A., Dauerman, H. L., Lala, A., McDermott, M. M., ... & Peer Review Task Force of the Scientific Publications Committee. (2023). Challenges and controversies in peer review: JACC review topic of the week. Journal of the American College of Cardiology, 82(21), 2054-2062. 484 Hall, R. P. (2022). Effective peer review: who, where, or what?. JID Innovations, 2(6). 485 Nguyen, D. D., Murayama, A., Nguyen, A. L., Cheng, A., Murad, L., Satkunasivam, R., & Wallis, C. J. (2024). Payments by drug and medical device manufacturers to US peer reviewers of major medical journals. JAMA, 332(17), 1480-1482. 486 Lexchin, J., Bero, L. A., Djulbegovic, B., & Clark, O. (2003). Pharmaceutical industry sponsorship and research outcome and quality: systematic review. bmj, 326(7400), 1167-117. 487 Stamatakis, E., Weiler, R., & Ioannidis, J. P. (2013). Undue industry influences that distort healthcare research, strategy, expenditure and practice: a review. European journal of clinical investigation, 43(5), 469-475. 488 Sharma, S., Booth, C. M., Eisenhauer, E. A., & Gyawali, B. (2021). Do editorialists with industry-related conflicts of interest write unduly favorable editorials for cancer drugs in top journals?. Journal of the National Comprehensive Cancer Network, 19(11), 1258-1263.